Furthermore, two patients developed a recurrence before the start of consolidation therapy: one had a KRAS/STK11 co-mutation and the other had an ALK rearrangement, a finding that suggests that molecular analysis in unresectable NSCLC would be of value to identify the patients expected to benefit or not from CRT/ICI combinations. This evidence concerns the gene STK11 and non-small cell lung carcinoma.